期刊文献+

盐酸乐卡地平的合成 被引量:5

Synthesis of Lercanidipine Hydrochloride
下载PDF
导出
摘要 以肉桂酸、氯化亚砜、甲胺等为原料经傅克烷烃化、酰氯化、酰胺化,再用KBH4/ZnC l2体系还原酰胺得到中间体N-甲基-3,3-二苯基丙胺Ⅴ;以2-甲基烯丙基氯为原料,经水合得到中间体1-氯-2-甲基-2-丙醇Ⅵ;再由Ⅴ、Ⅵ合成关键中间体侧链醇2,N-二甲基-N-(3,3-二苯基丙基)-1-氨基-2-丙醇Ⅶ,最后和母核1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-5-甲氧羰基-3-吡啶羧酸(DHPCOOH)对接得到乐卡地平Ⅷ,6步反应总得率23.2%,各中间体及产物结构经MS以及1HNMR确证。 Alkylation of benzene with cinnamic acid ( Ⅰ ) via Fridel-Crafts reaction gave 3,3-diphenylpropanoic acid ( Ⅱ ), which was subsequently converted into the corresponding acid chloride ( Ⅲ ) and further converted into N-methyl-3,3-diphenylpropanamide (Ⅳ) by reaction with methylamine in methanol. Ⅳ was efficiently reduced with the KBHa/ZnCl2 system to give N-methyl-3, 3- diphenylpropanamine ( Ⅴ ). 2-Methylallyl chloride was hydrated with 80% sulfuric acid to get 1-chloro- 2-methyl-2-propanol(Ⅵ). Then Ⅴ reacted with Ⅵ to get the key intermediate 2,N-dimethyl-N-(3,3- diphenylpropyl ) -1-amino-2-propanol ( Ⅶ ). Finally, Ⅶ and 2, 6-dimethy4-( 3-nitrophenyl ) -5- methoxycarboxyl-1,4-dihydropyridine-3-carboxylic acid(DHPCOOH) were connected to form the target product lercanidipine hydrochloride (Ⅷ). Total yield of the seven steps was 23.2%, and structures of the product Ⅷ and key intermediates were verified by ESI -MS and ^1HNMR.
出处 《精细化工》 EI CAS CSCD 北大核心 2005年第12期950-951,954,共3页 Fine Chemicals
关键词 2 N-二甲基-N-(3 3-二苯基丙基)-1-氨基-2-丙醇 乐卡地平 2, N-dimethyl-N- ( 3,3 -dlphenylpropyl ) -1 -amino-2-propanol lercanidipine
  • 相关文献

参考文献5

  • 1Herbette L G,Vecchiarelli M,Leonadi A.Lercanidipine:short plasma half-life,long duration of action.A molecular model to rationalize its pharmacokinetic properties[J].J Cardiovasc Pharmacol,1997,29(Suppl 1):19-24.
  • 2Nardi,Dante Leonardi,Amedeo Graziani,et al.N-(3,3-diphenyl-propyl) aminoethyl esters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid,compositions and use[P].US:4 705 797,1987-11-10.
  • 3Amedeo L,Gianni M,Renzo P,et al.Asymmetric N-(3,3-diphenylpropyl) aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity[J].Eur J Med Chem,1998,33(5):399-420.
  • 4《全国原料药生产工艺汇编》编写组.全国原料药生产工艺汇编[M].上海:中国医药工业出版社,1979.997-999.
  • 5Burgin G,Hearne G,Rust F.Derivatives of allylic chlorides.Reaction of methallyl chlorides involving the double bond[J].Ind Eng Chem,1941,33(3):385-388.

共引文献2

同被引文献53

  • 1陈玉彬,白树华.1,4-二氢-2,6-二甲基-4-(间硝基苯基)-5-甲氧羰基-3-吡啶羧酸合成工艺研究[J].沈阳药科大学学报,2000,17(z1):11-12. 被引量:1
  • 2王巍.药品行政保护品种介绍:心血管药物(二)(续完)[J].中国新药与临床杂志,2005,24(3):229-230. 被引量:2
  • 3李坤,杜玉民,王海荣.1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶二羧酸单甲酯的制备[J].中国医药工业杂志,2006,37(3):153-154. 被引量:3
  • 4杨贯羽,宋延林,嵇耀武,黄志新.1,4-二氢吡啶类化合物的合成[J].郑州大学学报(自然科学版),1996,28(2):86-89. 被引量:9
  • 5KANSARA R,PATEL N, REHANI R,et al. A process for the preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative:WO, 2005/107374 A2 [ P ]. 2005 - 11 - 17.
  • 6REDDY P,REDDY R,REDDY M. A novel process for the preparation of Lercanidipine :WO ,2006/134606 A1 [ P]. 2006 - 12 - 21.
  • 7TOMER Z. Intermediates for the preparation of Lercanidipine: WO ,2006/059332 A1 [ P]. 2006 -06 -08.
  • 8CORSINI A, ACCOMAZZO MR, CANAVESI M. et al. The new calcium antagonist lercan-idiplne and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved ? [ J ]. Blood Press Suppl, 1998,7 ( 2 ) : 18 - 22.
  • 9CORSINI A, BONFATTI M, QUARATO P,et al. Effect of the new calcium antagonist lercanidiplne and its enantiomers on the migration and proliferation of arterial myocytes [ J ]. J Cardlovasc Pharmacol, 1996,28 (5) :687 - 694.
  • 10SABBATINI M, LEONARDI A, TESTA R, et al. Effects of dihydropyridine-type Ca^2 + antagonists on the renal arterial tree in spontaneously hypertensive rats [ J ] . J Cardlovasc Pharmacol, 2002,39(1) :39 -48.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部